Proteogenomic studies aimed at understanding ovarian tumor responses to agents targeting the DNA damage response and translating this knowledge into clinical benefit

蛋白质组学研究旨在了解卵巢肿瘤对针对 DNA 损伤反应的药物的反应，并将这些知识转化为临床益处

• 批准号: 10287121
• 负责人: Michael Birrer
• 金额: --
• 依托单位: FRED HUTCHINSON CANCER RESEARCH CENTER
• 依托单位国家: 美国
• 财政年份: 2017
• 资助国家: 美国
• 起止时间: 2017-06-01 至 2022-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10287121
• 关键词: Alzheimer' s Disease; Alzheimer' s disease brain; Biological Assay; Clinical; Communities; Complement; Complex; DNA Damage; Data; Diagnosis; Drug resistance; Functional disorder; Immune; Immune system; Immunoassay; Inflammation; Innate Immune Response; Knowledge; Malignant Female Reproductive System Neoplasm; Malignant Neoplasms; Malignant neoplasm of ovary; Mass Spectrum Analysis; Methodology; Natural Immunity; Operative Surgical Procedures; Parents; Proteins; Protocols documentation; Research; Resistance; Resistance development; Resources; Signal Transduction; Standardization; Time; Translating; Translational Research; Validation; Woman; Work; base; behavioral study; brain tissue; cancer cell; chemotherapy; immunoregulation; multiple reaction monitoring; multiplex assay; novel; novel strategies; novel therapeutics; open source; ovarian neoplasm; proteogenomics; response; targeted agent; therapeutic target; tumor progression

ABSTRACT We will provide the Alzheimer’s disease (AD) community with a novel assay resource based on advanced methodology that enables precise, highly specific, standardizable, multiplex quantification of the innate immunity- complement protein network in AD brain tissues. The innate immune response and its ties to inflammation are important to the pathophysiology of AD and represents a viable therapeutic target. Regulation of the immune system is the result of interplay amongst many 100s of proteins, and conventional protein quantification approaches (e.g. immunoassays) typically target one analyte at a time, which is not adequate for studying the behavior of a complex and robust signaling network such as innate immunity. We will develop multiplex assays to quantify proteins in the innate immune network, using a NextGen protein quantification platform based on a targeted form of mass spectrometry called multiple reaction monitoring (MRM). All assay protocols and validation data will be made publicly available as a novel resource to the community via the established, open-source NCI Assay Portal (assays.cancer.gov). We believe that this work is likely to stimulate additional work leading to progress on AD by providing the AD community with a novel assay resource based on advanced methodology that enables precise, highly specific, standardizable, multiplex quantification of the inflammation / innate immunity protein network in AD brains.

抽象的 我们将为阿尔茨海默氏病（AD）社区提供基于先进的新颖性 可以实现先天免疫力的精确，高度特定，可标准化的多重量化的方法。 AD脑组织中的蛋白质网络。 对AD的病理生理学重要，代表了可行的治疗靶标。 系统是许多100蛋白之间相互作用的结果，以及常规的蛋白质定量 方法（例如免疫测定）通常一次针对一个分析物，这不足以研究您 复杂而稳健的信号网络（例如INATE免疫）。 使用临时蛋白质定量平台低音低下 质谱的靶向形式称为多个反应监测（MRM）。 数据将通过已建立的开源NCI公开作为社区的无新颖资源。 测定门户（Assays.cancer.gov）。 通过为广告社区提供基于高级方法论的新型测定资源，从而取得广告的进展 这使炎症 /先天性的精确，高度特定，可标准化的多重量化 AD大脑中的免疫蛋白网络。